Trials / Completed
CompletedNCT02301364
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.
Conditions
- Lymphoma
- Primary Central Nervous System Lymphoma
- Recurrent/Refractory Secondary Central Nervous System Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buparlisib (BKM120) | Buparlisib 100 mg once daily. |
Timeline
- Start date
- 2014-11-20
- Primary completion
- 2016-10-11
- Completion
- 2016-10-11
- First posted
- 2014-11-25
- Last updated
- 2017-10-19
- Results posted
- 2017-10-19
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02301364. Inclusion in this directory is not an endorsement.